Bio Solution KRX:086820KOSDAQ
바이오솔루션 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days0
Articles tracked26since Sep 11
In Q2 2026, Bio Solution reported revenue of ₩4.7bn, up 50.1% year on year, and an operating loss of ₩482m. Bio Solution (바이오솔루션) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Oct 27 with 1 article.
Filing signals 4 quarters of losses Screener
Bio Solution quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩4.7bn | +50.1% | −₩482m margin −10.3% | −₩736m |
| Q1 2026 | ₩3.8bn | +19.9% | −₩1.3bn margin −34.5% | −₩2.0bn |
| Q4 2025 derived | ₩4.4bn | +23.2% | −₩485m margin −11.0% | ₩5.5bn |
| Q3 2025 | ₩4.5bn | +31.4% | −₩1.1bn margin −24.4% | −₩1.9bn |
| Q2 2025 | ₩3.1bn | -4.9% | −₩1.4bn margin −44.0% | −₩950m |
| Q1 2025 | ₩3.1bn | +21.8% | −₩1.4bn margin −43.9% | −₩2.4bn |
| Q4 2024 derived | ₩3.6bn | +2.2% | −₩476m margin −13.3% | −₩5.2bn |
| Q3 2024 | ₩3.4bn | +7.8% | −₩1.3bn margin −36.6% | −₩2.6bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Bio Solution top stories 2 weeks, by number of outlets
- 1
Latest Bio Solution news Korean headlines
-
바이오솔루션, 글로벌 시험기관 참여 ISO 국제표준화 검증연구 추진
1 more on this story · 1 outlets
- 바이오솔루션 '솔루오랄', ISO 국제표준화 검증연구 추진뉴스핌 · Oct 13 11:20
-
바이오솔루션, 中 CGT 포럼서 카티라이프·차세대 파이프라인 소개
1 more on this story · 1 outlets
- 바이오솔루션, 中 CGT 포럼서 ‘카티라이프’ 상용화 경험·차세대 파이프라인 공개한국경제 · Oct 6 11:32
-
[더벨]바이오솔루션, 광저우 CGT 포럼서 연골재생, 골관절염 치료제 소개
3 more on this story · 2 outlets
- 바이오솔루션, 카티라이프 中 진출 본격화…광저우 CGT 포럼서 소개이데일리 · Oct 6 10:00
- 바이오솔루션, 카티라이프 中 진출 본격화…광저우 CGT 포럼서 소개이데일리 · Oct 6 10:01
- 바이오솔루션, ‘카티라이프’ 中 진출 본격화…“광저우 CGT 포럼서 소개”더바이오 · Oct 6 10:17